FLT3 and acute myeloid leukemia: The second consisted of multi-omics data from a murine acute myeloid leukemia (AML) cell line treated with ac220, a tyrosine kinase inhibitor (TKIs) targeting the FMS‐like tyrosine kinase 3 (Flt3), as described in our previous work20 (Supplementary Fig. 12).